Select your location

Asia Australia North America UK Europe Rest of the World

Select your investor type

Institutional investor

For consultants, pension schemes, insurers and professional investors

Important information

The information and material contained in this website are designed to provide information on Martin Currie and is only directed at Institutional Investors and Consultants.

By accepting where indicated, you hereby acknowledge, agree and represent to Martin Currie that you are eligible by confirming that you are based in the UK, you are an authorised to conduct regulated activities in the UK and that you have read and understood the "Legal & Regulatory Information", which applies to any investment in our products referred to in this website.

The information contained within this website does not constitute an offer of or an invitation to apply for securities:

In any jurisdiction where such offer or invitation is unlawful or
In which the person making such offer is not qualified to do so or
To whom it is unlawful to make such offer or solicitation.

Martin Currie Investment Management Limited is authorised and regulated in the UK by the Financial Conduct Authority.

The distribution of this information in written format is restricted to the UK. The information contained in this site has been compiled with considerable care to ensure its accuracy at the date of publication. But no representation or warranty, express or implied, is made to its accuracy or completeness. Any research or analysis contained in this website has been procured by Martin Currie for its own use. It is provided to you only incidentally, and any opinions expressed are subject to change without notice.
Accept and enter

Intermediary investor

For advisors, professional wealth managers and wholesale investors

Important information

The information and material contained in this website are designed to provide information on Martin Currie and is only directed at Institutional Investors and Consultants.

By accepting where indicated, you hereby acknowledge, agree and represent to Martin Currie that you are eligible by confirming that you are based in the UK, you are an authorised to conduct regulated activities in the UK and that you have read and understood the "Legal & Regulatory Information", which applies to any investment in our products referred to in this website.

The information contained within this website does not constitute an offer of or an invitation to apply for securities:

In any jurisdiction where such offer or invitation is unlawful or
In which the person making such offer is not qualified to do so or
To whom it is unlawful to make such offer or solicitation.

Martin Currie Investment Management Limited is authorised and regulated in the UK by the Financial Conduct Authority.

The distribution of this information in written format is restricted to the UK. The information contained in this site has been compiled with considerable care to ensure its accuracy at the date of publication. But no representation or warranty, express or implied, is made to its accuracy or completeness. Any research or analysis contained in this website has been procured by Martin Currie for its own use. It is provided to you only incidentally, and any opinions expressed are subject to change without notice.
Accept and enter

Select your investor type

Institutional investor

For consultants, pension schemes, insurers and professional investors

Please read this important information

Please read this important information. If you cannot make the representations below, please do not enter the website.

By clicking on this link, you agree and represent to Martin Currie that you are a resident of or incorporated in the United Kingdom have read and understood the "Important Information and Risk Factors", which apply to any investment in our products referred to in this website, and that you are categorised as a per se or elective Professional Client for the purposes of COBS 3 of the FCA Handbook or rules and guidance. The information on this section of the website is not intended for use by any other person, including members of the public.

Martin Currie Investment Management Limited, registered in Scotland (no SC066107) is authorised and regulated by the UK Financial Conduct Authority. Martin Currie Fund Management Limited, registered in Scotland (no SC104896) is authorised and regulated by the UK Financial Conduct Authority as a full-scope UK AIFM.

For the avoidance of doubt, nothing excludes, limits or restricts our obligations to you under the UK Financial Services and Market Act 2000 or any other applicable law or regulation.

The opinions and views in this website do not take into account your individual circumstances, objectives, or needs and are not intended to be recommendations of particular financial instruments or strategies to you. This website does not identify all the risks (direct or indirect) or other considerations which might be material to you when entering any financial transaction. You should consult with your professional advisers before undertaking any investment activity. The information provided on this website should not be treated as advice or a recommendation to buy or sell any particular security or other investment. The information on this website has not been reviewed by any competent regulatory authority.

Accept and enter

Intermediary investor

For advisors, professional wealth managers and wholesale investors

Please read this important information

Please read this important information. If you cannot make the representations below, please do not enter the website.

By clicking on this link, you agree and represent to Martin Currie that you are a resident of or incorporated in the United Kingdom have read and understood the "Important Information and Risk Factors", which apply to any investment in our products referred to in this website, and that you are categorised as a per se or elective Professional Client for the purposes of COBS 3 of the FCA Handbook or rules and guidance. The information on this section of the website is not intended for use by any other person, including members of the public.

Martin Currie Investment Management Limited, registered in Scotland (no SC066107) is authorised and regulated by the UK Financial Conduct Authority. Martin Currie Fund Management Limited, registered in Scotland (no SC104896) is authorised and regulated by the UK Financial Conduct Authority as a full-scope UK AIFM.

For the avoidance of doubt, nothing excludes, limits or restricts our obligations to you under the UK Financial Services and Market Act 2000 or any other applicable law or regulation.

The opinions and views in this website do not take into account your individual circumstances, objectives, or needs and are not intended to be recommendations of particular financial instruments or strategies to you. This website does not identify all the risks (direct or indirect) or other considerations which might be material to you when entering any financial transaction. You should consult with your professional advisers before undertaking any investment activity. The information provided on this website should not be treated as advice or a recommendation to buy or sell any particular security or other investment. The information on this website has not been reviewed by any competent regulatory authority.

Accept and enter

Private investor

For individuals

Please read this important information

This website is intended for, and is relevant to, UK residents only and should not be relied upon by persons of any other jurisdiction.

By accepting where indicated, you hereby acknowledge, agree and represent to Martin Currie that you are eligible by confirming that you are based in the UK and that you have read and understood the "Legal Regulatory Information" which applies to any investment in our products referred to in this website.

Important Information:

We do not give investment advice so you need to decide if an investment is suitable for you. If you are unsure whether to invest, you should contact a financial adviser.

Accept and enter

Select your investor type

Institutional investor

For consultants, pension schemes, insurers and professional investors

Please read this important information

By clicking on this link, you agree and represent to Martin Currie that you have read and understood the "Important information and risk factors", which apply to any investment in our products referred to in this website, and that you are incorporated in a country listed below and that you are either an institutional investor, a corporate professional investor or a consultant business. The information on this section of the website is not intended for use by any other person in any other jurisdiction, including members of the public. If you cannot make these representations, please do not enter the website.

All residents of Hong Kong: Neither Martin Currie Investment Management Limited nor Martin Currie Inc. carries on a business in a regulated activity in Hong Kong or is licensed by the Securities and Futures Commission. The content of this section of the website is intended for Professional Investors only.

All residents of Singapore: The information in this section of the website is intended for institutional investors (as defined in the Securities and Futures Act, Chapter 289 of Singapore, as amended) and consultants in Singapore only.

All residents of China: Neither Martin Currie Investment Management Limited nor Martin Currie Inc. is authorised by the China Securities Regulatory Commission to market its strategies in China. By clicking on this link, you warrant and represent that you are entering this website on your own initiative and without being influenced or induced by any third party to do so.

All residents of South Korea: The information in this section of the website is intended only for qualified professional investors and consultants based in South Korea.

Martin Currie Investment Management Limited, registered in Scotland (no SC066107). Martin Currie Inc, incorporated in New York and having a UK branch registered in Scotland (no SF000300), Saltire Court, 20 Castle Terrace, Edinburgh EH1 2ES Tel: (44) 131 229 5252 Fax: (44) 131 222 2532 www.martincurrie.com. Both companies are authorised and regulated by the UK Financial Conduct Authority. Martin Currie Inc, 620 Eighth Avenue, 49th Floor New York, NY 10018 is also registered with the Securities Exchange Commission as an investment adviser for the purposes of the Investment Advisers Act 1940.

For the avoidance of doubt, nothing excludes, limits or restricts our obligations to you under the UK Financial Services and Market Act 2000, the Investment Advisers Act 1940 or any other applicable law or regulation.

The opinions and views in this website do not take into account your individual circumstances, objectives, or needs and are not intended to be recommendations of particular financial instruments or strategies to you. This website does not identify all the risks (direct or indirect) or other considerations which might be material to you when entering any financial transaction. You should consult with your professional advisers before undertaking any investment activity. The information provided on this website should not be treated as advice or a recommendation to buy or sell any particular security or other investment. The information on this website has not been reviewed by any competent regulatory authority.

Accept and enter

Intermediary investor

For advisors, professional wealth managers and wholesale investors

Please read this important information

By clicking on this link, you agree and represent to Martin Currie that you have read and understood the "Important information and risk factors", which apply to any investment in our products referred to in this website, and that you are incorporated in a country listed below and that you are either an institutional investor, a corporate professional investor or a consultant business. The information on this section of the website is not intended for use by any other person in any other jurisdiction, including members of the public. If you cannot make these representations, please do not enter the website.

All residents of Hong Kong: Neither Martin Currie Investment Management Limited nor Martin Currie Inc. carries on a business in a regulated activity in Hong Kong or is licensed by the Securities and Futures Commission. The content of this section of the website is intended for Professional Investors only.

All residents of Singapore: The information in this section of the website is intended for institutional investors (as defined in the Securities and Futures Act, Chapter 289 of Singapore, as amended) and consultants in Singapore only.

All residents of China: Neither Martin Currie Investment Management Limited nor Martin Currie Inc. is authorised by the China Securities Regulatory Commission to market its strategies in China. By clicking on this link, you warrant and represent that you are entering this website on your own initiative and without being influenced or induced by any third party to do so.

All residents of South Korea: The information in this section of the website is intended only for qualified professional investors and consultants based in South Korea.

Martin Currie Investment Management Limited, registered in Scotland (no SC066107). Martin Currie Inc, incorporated in New York and having a UK branch registered in Scotland (no SF000300), Saltire Court, 20 Castle Terrace, Edinburgh EH1 2ES Tel: (44) 131 229 5252 Fax: (44) 131 222 2532 www.martincurrie.com. Both companies are authorised and regulated by the UK Financial Conduct Authority. Martin Currie Inc, 620 Eighth Avenue, 49th Floor New York, NY 10018 is also registered with the Securities Exchange Commission as an investment adviser for the purposes of the Investment Advisers Act 1940.

For the avoidance of doubt, nothing excludes, limits or restricts our obligations to you under the UK Financial Services and Market Act 2000, the Investment Advisers Act 1940 or any other applicable law or regulation.

The opinions and views in this website do not take into account your individual circumstances, objectives, or needs and are not intended to be recommendations of particular financial instruments or strategies to you. This website does not identify all the risks (direct or indirect) or other considerations which might be material to you when entering any financial transaction. You should consult with your professional advisers before undertaking any investment activity. The information provided on this website should not be treated as advice or a recommendation to buy or sell any particular security or other investment. The information on this website has not been reviewed by any competent regulatory authority.

Accept and enter

Select your investor type

Institutional investor

For consultants, Superannuation, insurers and professional investors

Please read this important information

By clicking on this link, you agree and represent to Martin Currie that you are an Australian wholesale client for the purposes of section 761G of the Corporations Act 2001 (Cth) and have read and understood the "Legal and Regulatory Information”", which apply to any investment in our products referred to in this website. The information on this section of the website is not intended for use by any other person, including members of the public. If you cannot make these representations, please do not enter the website.

Important Information:

Martin Currie Australia is a division of Legg Mason Asset Management Australia Limited (ABN 76 004 835 849). Legg Mason Asset Management Australia Limited holds an Australian Financial Services Licence (AFSL No. AFSL 240827) issued pursuant to the Corporations Act 2001.

Martin Currie Investment Management Limited, registered in Scotland (no SC066107) is authorised and regulated by the UK Financial Conduct Authority.

The FCA's regulatory regime differs from the Australian regulatory regime.
This material is provided on the basis that you are a wholesale client within the definition of ASIC Class Order 03/1099. Martin Currie is registered as a foreign company under the Corporations Act 2001 (ARBN 131 134 613). It is exempt from the requirement to hold an Australian Financial Services Licence under the Corporations Act 2001 in respect of financial services provided to Australian wholesale clients by virtue of the application of ASIC Class Order 03/1099.

The opinions and views in this website do not take into account your individual circumstances, objectives, or needs and are not intended to be recommendations of particular financial instruments or strategies to you. This website does not identify all the risks (direct or indirect) or other considerations which might be material to you when entering any financial transaction. You should consult with your professional advisers before undertaking any investment activity. The information provided on this website should not be treated as advice or a recommendation to buy or sell any particular security or other investment. The information on this website has not been reviewed by any competent regulatory authority.

Accept and enter

Intermediary investor

For advisors, professional wealth managers and wholesale investors

Please read this important information

By clicking on this link, you agree and represent to Martin Currie that you are an Australian wholesale client for the purposes of section 761G of the Corporations Act 2001 (Cth) and have read and understood the "Legal and Regulatory Information”", which apply to any investment in our products referred to in this website. The information on this section of the website is not intended for use by any other person, including members of the public. If you cannot make these representations, please do not enter the website.

Important Information:

Martin Currie Australia is a division of Legg Mason Asset Management Australia Limited (ABN 76 004 835 849). Legg Mason Asset Management Australia Limited holds an Australian Financial Services Licence (AFSL No. AFSL 240827) issued pursuant to the Corporations Act 2001.

Martin Currie Investment Management Limited, registered in Scotland (no SC066107) is authorised and regulated by the UK Financial Conduct Authority.

The FCA's regulatory regime differs from the Australian regulatory regime.
This material is provided on the basis that you are a wholesale client within the definition of ASIC Class Order 03/1099. Martin Currie is registered as a foreign company under the Corporations Act 2001 (ARBN 131 134 613). It is exempt from the requirement to hold an Australian Financial Services Licence under the Corporations Act 2001 in respect of financial services provided to Australian wholesale clients by virtue of the application of ASIC Class Order 03/1099.

The opinions and views in this website do not take into account your individual circumstances, objectives, or needs and are not intended to be recommendations of particular financial instruments or strategies to you. This website does not identify all the risks (direct or indirect) or other considerations which might be material to you when entering any financial transaction. You should consult with your professional advisers before undertaking any investment activity. The information provided on this website should not be treated as advice or a recommendation to buy or sell any particular security or other investment. The information on this website has not been reviewed by any competent regulatory authority.

Accept and enter

Select your investor type

Institutional investor

For consultants, pension schemes, insurers and professional investors

Please read this important information

Please read this important information. The information on this section of the website is not intended for use by any other person in any other jurisdiction, including members of the public. If you cannot make the following representations, please do not enter the website.

All residents of Luxembourg, Republic of Ireland, Netherlands, Germany, Sweden, Finland, Norway, Denmark, Italy, Belgium and France: By clicking on this link, you agree and represent to Martin Currie that you have read and understood the "Important information and risk factors", which apply to any investment in our products referred to in this website, and that you are categorised as a per se or elective Professional Client for the purposes of Directive 2014/65/EU (“MiFID II”). The information on this section of the website is not intended for use by any other person, including members of the public.

All residents of Switzerland: By clicking on this link, you agree and represent to Martin Currie that you have read and understood the "Important information and risk factors", which apply to any investment in our products referred to in this website, and that that you are resident in or incorporated in Switzerland and that you are a Qualified Investor for the purposes of Article 10 of the Collective Investment Schemes Act. The information on this section of the website is not intended for use by any other person, including members of the public.

Martin Currie Investment Management Limited, registered in Scotland (no SC066107) is authorised and regulated by the UK Financial Conduct Authority. Martin Currie Investment Management Limited has a MiFID II passport to provide investment services to Professional Clients in the European Union.

For the avoidance of doubt, nothing excludes, limits or restricts our obligations to you under the UK Financial Services and Market Act 2000 or any other applicable law or regulation.

The opinions and views in this website do not take into account your individual circumstances, objectives, or needs and are not intended to be recommendations of particular financial instruments or strategies to you. This website does not identify all the risks (direct or indirect) or other considerations which might be material to you when entering any financial transaction. You should consult with your professional advisers before undertaking any investment activity. The information provided on this website should not be treated as advice or a recommendation to buy or sell any particular security or other investment. The information on this website has not been reviewed by any competent regulatory authority.

Accept and enter

Intermediary investor

For advisors, professional wealth managers and wholesale investors

Please read this important information

Please read this important information.

All residents of Luxembourg, Republic of Ireland, Netherlands, Germany, Sweden, Finland, Norway, Denmark, Italy, Belgium and France: By clicking on this link, you agree and represent to Martin Currie that you have read and understood the "Important information and risk factors", which apply to any investment in our products referred to in this website, and that you are categorised as a per se or elective Professional Client for the purposes of Directive 2014/65/EU (“MiFID II”). The information on this section of the website is not intended for use by any other person, including members of the public.

All residents of Switzerland: By clicking on this link, you agree and represent to Martin Currie that you have read and understood the "Important information and risk factors", which apply to any investment in our products referred to in this website, and that that you are resident in or incorporated in Switzerland and that you are a Qualified Investor for the purposes of Article 10 of the Collective Investment Schemes Act. The information on this section of the website is not intended for use by any other person, including members of the public.

Martin Currie Investment Management Limited, registered in Scotland (no SC066107) is authorised and regulated by the UK Financial Conduct Authority. Martin Currie Investment Management Limited has a MiFID II passport to provide investment services to Professional Clients in the European Union.

For the avoidance of doubt, nothing excludes, limits or restricts our obligations to you under the UK Financial Services and Market Act 2000 or any other applicable law or regulation.

The opinions and views in this website do not take into account your individual circumstances, objectives, or needs and are not intended to be recommendations of particular financial instruments or strategies to you. This website does not identify all the risks (direct or indirect) or other considerations which might be material to you when entering any financial transaction. You should consult with your professional advisers before undertaking any investment activity. The information provided on this website should not be treated as advice or a recommendation to buy or sell any particular security or other investment. The information on this website has not been reviewed by any competent regulatory authority.

Accept and enter

Select your investor type

Institutional investor

For consultants, pension schemes, insurers and professional investors

Please read this important information. If you cannot make either of the representations below, please do not enter the website.

Investors resident in the Canada: By clicking on this link, you agree and represent to Martin Currie that you have read and understood the "Important information and risk factors", which apply to any investment in our products referred to in this website, and that you are resident in, or incorporated in, Canada and are a Permitted Client for the purposes of NI 31-103. The information on this section of the website is not intended for use by any other person, including members of the public.

Investors resident in the United States of America: By clicking on this link, you agree and represent to Martin Currie that you have read and understood the "Important information and risk factors", which apply to any investment in our products referred to in this website, and that you are either incorporated in, or a resident of, the United States of America and that you meet the definition of an Accredited Investor as defined in Rule 501 of the United States Securities Act of 1933, as amended (‘The 1933 Act’). The information on this section of the website is not intended for use by any other person in any other jurisdiction, including members of the public.

Martin Currie Inc, incorporated in New York with its registered office at 620 Eighth Avenue, 49th Floor New York, NY 10018 and having a UK branch registered in Scotland (no SF000300), Saltire Court, 20 Castle Terrace, Edinburgh EH1 2ES Tel: (44) 131 229 5252 Fax: (44) 131 222 2532 www.martincurrie.com, is registered with the Securities Exchange Commission as an investment adviser for the purposes of the Investment Advisers Act 1940 and is also authorised and regulated by the UK Financial Conduct Authority. Martin Currie Inc. operates under the International Adviser Exemption with the Ontario Securities Commission (‘OSC’) and is therefore currently not required to be registered as a portfolio manager for the purposes of MI 31-103.

For the avoidance of doubt, nothing excludes, limits or restricts our obligations to you under the UK Financial Services and Market Act 2000, the Investment Advisers Act 1940, National Instruments or any other applicable law or regulation.

The opinions and views in this website do not take into account your individual circumstances, objectives, or needs and are not intended to be recommendations of particular financial instruments or strategies to you. This website does not identify all the risks (direct or indirect) or other considerations which might be material to you when entering any financial transaction. You should consult with your professional advisers before undertaking any investment activity. The information provided on this website should not be treated as advice or a recommendation to buy or sell any particular security or other investment. The information on this website has not been reviewed by any competent regulatory authority.

Accept and enter

Intermediary investor

For advisors, professional wealth managers and wholesale investors

Please read this important information

Investors resident in the Canada: By clicking on this link, you agree and represent to Martin Currie that you have read and understood the "Important information and risk factors", which apply to any investment in our products referred to in this website, and that you are resident in, or incorporated in, Canada and are a Permitted Client for the purposes of NI 31-103. The information on this section of the website is not intended for use by any other person, including members of the public.

Investors resident in the United States of America: By clicking on this link, you agree and represent to Martin Currie that you have read and understood the "Important information and risk factors", which apply to any investment in our products referred to in this website, and that you are either incorporated in, or a resident of, the United States of America and that you meet the definition of an Accredited Investor as defined in Rule 501 of the United States Securities Act of 1933, as amended (‘The 1933 Act’). The information on this section of the website is not intended for use by any other person in any other jurisdiction, including members of the public.

Martin Currie Inc, incorporated in New York with its registered office at 620 Eighth Avenue, 49th Floor New York, NY 10018 and having a UK branch registered in Scotland (no SF000300), Saltire Court, 20 Castle Terrace, Edinburgh EH1 2ES Tel: (44) 131 229 5252 Fax: (44) 131 222 2532 www.martincurrie.com, is registered with the Securities Exchange Commission as an investment adviser for the purposes of the Investment Advisers Act 1940 and is also authorised and regulated by the UK Financial Conduct Authority. Martin Currie Inc. operates under the International Adviser Exemption with the Ontario Securities Commission (‘OSC’) and is therefore currently not required to be registered as a portfolio manager for the purposes of MI 31-103.

For the avoidance of doubt, nothing excludes, limits or restricts our obligations to you under the UK Financial Services and Market Act 2000, the Investment Advisers Act 1940, National Instruments or any other applicable law or regulation.

The opinions and views in this website do not take into account your individual circumstances, objectives, or needs and are not intended to be recommendations of particular financial instruments or strategies to you. This website does not identify all the risks (direct or indirect) or other considerations which might be material to you when entering any financial transaction. You should consult with your professional advisers before undertaking any investment activity. The information provided on this website should not be treated as advice or a recommendation to buy or sell any particular security or other investment. The information on this website has not been reviewed by any competent regulatory authority.

Accept and enter

Select your investor type

Institutional investor

For consultants, pension schemes, insurers and professional investors

Please read this important information

Please read this important information. If you cannot make the representations below, please do not enter the website.

By clicking on this link, you agree and represent to Martin Currie that you have read and understood the "Important information and risk factors", which apply to any investment in our products referred to in this website, and that: (i) you are an institutional investor, an intermediary investor a consultant or other professional investor; and (ii) you are entering this website on your own initiative and without being influenced or induced by any third party to do so. The information on this section of the website is not intended for use by any other person, including members of the public.

Martin Currie Investment Management Limited, registered in Scotland (no SC066107). Martin Currie Inc, incorporated in New York and having a UK branch registered in Scotland (no SF000300), Saltire Court, 20 Castle Terrace, Edinburgh EH1 2ES Tel: (44) 131 229 5252 Fax: (44) 131 222 2532 www.martincurrie.com. Both companies are authorised and regulated by the UK Financial Conduct Authority. Martin Currie Inc, 620 Eighth Avenue, 49th Floor New York, NY 10018 is also registered with the Securities Exchange Commission as an investment adviser for the purposes of the Investment Advisers Act 1940.

For the avoidance of doubt, nothing excludes, limits or restricts our obligations to you under the UK Financial Services and Market Act 2000, the Investment Advisers Act 1940 or any other applicable law or regulation. The information on this website has not been reviewed by any competent regulatory authority in any jurisdiction.

The opinions and views in this website do not take into account your individual circumstances, objectives, or needs and are not intended to be recommendations of particular financial instruments or strategies to you. This website does not identify all the risks (direct or indirect) or other considerations which might be material to you when entering any financial transaction. You should consult with your professional advisers before undertaking any investment activity. The information provided on this website should not be treated as advice or a recommendation to buy or sell any particular security or other investment. The information on this website has not been reviewed by any competent regulatory authority.

Accept and enter

Intermediary investor

For advisors, professional wealth managers and wholesale investors

Please read this important information

Please read this important information. If you cannot make the representations below, please do not enter the website.

By clicking on this link, you agree and represent to Martin Currie that you have read and understood the "Important information and risk factors", which apply to any investment in our products referred to in this website, and that: (i) you are an institutional investor, an intermediary investor a consultant or other professional investor; and (ii) you are entering this website on your own initiative and without being influenced or induced by any third party to do so. The information on this section of the website is not intended for use by any other person, including members of the public.

Martin Currie Investment Management Limited, registered in Scotland (no SC066107). Martin Currie Inc, incorporated in New York and having a UK branch registered in Scotland (no SF000300), Saltire Court, 20 Castle Terrace, Edinburgh EH1 2ES Tel: (44) 131 229 5252 Fax: (44) 131 222 2532 www.martincurrie.com. Both companies are authorised and regulated by the UK Financial Conduct Authority. Martin Currie Inc, 620 Eighth Avenue, 49th Floor New York, NY 10018 is also registered with the Securities Exchange Commission as an investment adviser for the purposes of the Investment Advisers Act 1940.

For the avoidance of doubt, nothing excludes, limits or restricts our obligations to you under the UK Financial Services and Market Act 2000, the Investment Advisers Act 1940 or any other applicable law or regulation. The information on this website has not been reviewed by any competent regulatory authority in any jurisdiction.

The opinions and views in this website do not take into account your individual circumstances, objectives, or needs and are not intended to be recommendations of particular financial instruments or strategies to you. This website does not identify all the risks (direct or indirect) or other considerations which might be material to you when entering any financial transaction. You should consult with your professional advisers before undertaking any investment activity. The information provided on this website should not be treated as advice or a recommendation to buy or sell any particular security or other investment. The information on this website has not been reviewed by any competent regulatory authority.

Accept and enter

If none of the above applies to you, please go to our corporate site.

A critical juncture for China's pharmaceutical industry

The Chinese pharmaceutical sector is at a critical juncture. The external industry environment, where both multinational corporations (MNCs) and domestic players operate is undergoing transformational changes impacted by a series of regulatory reforms.

Andrew Graham Head of Asia
Zhang Yu Investment Analyst

Significant industry change

The Chinese pharmaceutical sector is at a critical juncture. The external industry environment, where both multinational corporations (MNCs) and domestic players operate is undergoing transformational changes impacted by a series of regulatory reforms. The most significant of these is the implementation of a new type of mechanism for drug procurement and pricing through:

  1. The volume-based Centralized Procurement system (CP)
  2. and the National Drug Reimbursement List (NDRL) negotiations.

The centralized procurement system (CP)

At this critical juncture in the industry, we believe it is the companies that can evolve the fastest which will survive and thrive.

Endorsed by China's leadership, the newly formed and super-powerful medical insurance fund agency, the State Medical Insurance Administration (SMIA) was behind the significant policy innovation of Centralized Procurement (CP). Under this, SMIA organises public tenders for drugs on the medical insurance reimbursements lists by offering guaranteed volumes to winners, thereby encouraging participants to bid much lower prices.

The guaranteed volumes represent between 50%–80% of the total annual usage of the chosen drug categories in all public hospitals across the entire country. The rules of CP were refined and adjusted over the past year from initially allowing only a single winner for a limited number of drug categories during the first-round trial implementation in 11 cities, to allowing multiple winners in the latest second-round tender involving 33 drug categories over a national basis.

During the two rounds of CP conducted in December 2018 and January 2020, the final tender prices both fell by an average of 50% versus original market price, with some down as much as 90%. The steep price cuts mean the primary policy goal of achieving large savings on medical insurance spending was accomplished; ironically, it also highlights the long-standing structural issue within China’s pharma industry - specifically, the excessively high drug price1.

Understanding the reasons for high prices

High drug cost is a complicated matter with several important factors at play, but at the core is the issue of ‘prescription power’.

  • The predominant current drug tender system in China is conducted on a provincial basis under the purview of local health administration bodies. However, unlike a complete tender process, the local health administrations only oversee the pricing negotiation part, without actually fulfilling the purchasing and payment of drugs. Hospitals, the purchasers, are required to purchase drugs at the set price and the Ministry of Human Resources and Social Security (MoHRSS), the payer, will pick up the bill. The segregation had led to a fundamental misalignment of incentives, which combined with a poor accountability mechanism, had impaired the system’s ability to carry out powerful and effective drug price negotiation. This led to only a limited price cut during the provincial tenders.
  • A tiered pricing system is another key reason behind historically high drug prices. Under this mechanism, pricing is differentiated according to MNCs’ branded drugs, first-to-market domestic generic drugs and other domestic generic drugs; this has led to different price discount levels during tender price negotiations. Originally, tiered pricing was adopted to reflect drug quality differences, which was necessary due to the lack of a robust generic drug approval process in China, such as mandatory bioequivalence testing (BE)2. As a result of tiered pricing, branded drugs sold in China can command a much higher premium over other generics, even after patent expiry, which gives rise to the anomaly of not having the ‘patent cliff’ in China.
  • China’s public hospital market – the actual purchaser of medicines – has very high entry barriers, which is another culprit for high drug costs. Current prescription administrative regulation stipulates that for any given drug with the same generic name, public hospitals cannot procure from more than two manufacturers. This is called the ‘1 category 2 products’ rule, which is put in place to prevent sales bribery. The consequences are that for any given drug category, hospitals normally procure one MNC’s branded drug for its superior quality and efficacy and one domestic generic drug for its cheaper price. This has ended up further reinforcing the pricing power of branded drugs even after their patent expiry. On the other hand, dozens or potentially even hundreds of domestic generic drug makers fight each other over the only other spot left to sell into the public hospital market, which accounts for the vast majority of the total drug market in China. What domestic generic makers compete on first and foremost is the sales capability, since there is little point competing on quality. Sales activities are unfortunately prone to corruption in the form of rebates to individuals with purchase decision-making powers (prescription power) at public hospitals. Admittedly, compensation levels of doctors in China are significantly lower than their counterparties in developed countries in both absolute and relative terms, which leads to the reliance on kickbacks on drug prescriptions as an important additional source of income.

The steep price cuts mean the primary policy goal of achieving large savings on medical insurance spending was accomplished...

The industry impact of CP

The incumbent procurement and pricing system has reduced the competition between brand drugs and generic drugs by allowing the former to command a price premium. For instance, the top-two largest suppliers to public hospitals in China have for a long time been two MNCs: Pfizer and AstraZeneca. At the same time, the selling expenses that domestic generic makers are paying to gain access to the public hospital market and to protect their market share thereafter are ultimately reflected in their drug prices.

Volume-based centralized procurement is designed to address these issues from the root by: 1) establishing a new national agency, the SMIA which is fully empowered and held accountable to ensure efficient policy making and execution3; 2) requiring mandatory BE testing as a prerequisite to be deemed eligible for CP, thereby eliminating drug quality differences and pricing differences between branded and generic drugs; 3) taking prescription power away from hospitals and doctors by centralising drug procurement, which in turn breaks down hospital entry barriers.

Enforcing the policy

The upheaval of drug procurement and pricing policy has unsurprisingly received much resistance from the industry. The regulators have implemented a raft of supplementary polices to ensure implementation.

Some examples include a ‘two-invoice policy’ and a ‘National Drug Monitoring List’. The former aims to reduce distribution layers – a natural place to hide and launder the ‘off-the-book expenses’, while the latter is a list of drugs that are among the highest-selling categories at hospitals, but which lack convincing clinical data to back efficacy. The majority are classified as adjuvant drugs or TCM (Traditional Chinese Medicine) injectables. Both are characterised by having ambiguous clinical benefit as well as broad and vague off-label indications. As such, they have long been a hotbed of corruption and over-prescription. Drugs on this list will be removed from medical insurance coverage and prescriptions strictly monitored.

Lastly, enhanced prescription monitoring and assessment mechanisms at public hospitals which are linked to compensation and promotion for doctors and executives, have been developed to ensure effective implementation of all policies with the focus on ensuring winners of CP are procured and prescribed at hospitals.

As important as reducing the cost of generic drug prices, improving drug quality and development of high efficacy innovative drugs are also the primary focus of China’s healthcare reform.

The absence of a BE standard has led to an oversupply of sub-standard generic products. As domestic pharma companies have long been focused on establishing a competitive advantage based on powerful sales and promotion capability. This has resulted in low R&D investment levels to the detriment of the overall competitiveness of this strategically important sector. The reform therefore serves to not only promote the proper use of medical insurance funds, but also encourage R&D investments to improve drug quality and the overall industry competitiveness.

The National Drug Reimbursement List (NDRL)

NDRL negotiations led by the SMIA is another price-regulating mechanism. However, unlike CP which is designed to bring down prices of ‘off-patent’ branded drugs and their generics, NDRL negotiations specifically target patented drugs. It is a drug-selection and price-negotiation process carried out between a panel of pharmacoeconomic experts and an individual pharmaceutical company to make decisions on drug inclusion into the national medical insurance fund4.

Evidence of price reductions

NDRL negotiations, like CP, usually lead to a material price cut. So far, three rounds of NDRL negotiations have taken place involving 36, 17, 119 drugs respectively with the latest round being conducted in November 2019. The accompanying price cuts were 44%, 57% and 61% respectively5. Despite the significant price cuts, pharmaceutical companies have strong incentives in participating in NDRL negotiations with the hope of gaining significant volume upside which would normally offset average selling price (ASP) erosion. The level of price cut resulting from NDRL negotiation is determined by the competitive landscape of the respective treatment area, while the key to standing out from the competition is drug efficacy (as demonstrated by better clinical data), and to a lesser extent the cost advantage; CP, on the other hand, is a competition solely on price.

R&D a differentiator

The direction of reform and policy have profound impacts on a company’s strategy, R&D direction and capacity plans. Those that could withstand severe price cuts and thrive in the future competitive landscape are leaders in innovation, R&D efficiency, manufacturing quality and cost. A number of Chinese pharma companies have emerged that exhibit strong product development and R&D strategies. The most prominent examples include large pharmaceutical firms such as Jiangsu Hengrui, Sino Biopharmaceutical and CSPC, as well as small biotech firms like BeiGene.

As important as reducing the cost of generic drug prices, improving drug quality and development of high efficacy innovative drugs are also the primary focus of China’s healthcare reform.

Alternative R&D strategies

Chinese pharmaceutical companies are likely to continue to adopt the ‘me-too’ & ‘fast follower’ strategy by rapidly following global R&D hot areas in terms of mechanisms/ targets and developing differentiated molecules as these potentailly offer a higher R&D return and lower risk. For example, leading Chinese pharma companies have already demonstrated great competitiveness in developing PD-1 monoclonal antibodies (one of the most advanced oncology therapy drugs) and are well placed to benefit from the push towards these types of drugs, for instance, via faster approvals, inclusions in the NDRL, very low current penetration, less price pressure and higher demand elasticity.

On the generic drug front, leading domestic generic makers have adopted the following strategies:

  • Use of high barrier generics to fend off competition; for example, innovation in drug formulation to improve active pharmaceutical ingredient (API) bioavailability;
  • Commanding a vertically integrated API capability to establish cost and capacity advantage; steady supply and quality consistency are the crucial criteria to win CP tenders;
  • The development of biosimilar drugs (monoclonal antibodies) with intrinsically high barriers due to significant investment requirements and deep learning curves which hinders new entrants;
  • The development of better efficacy generated by incremental innovation compared with brand drugs.

While some industry leaders have struggled to adapt, others have already started self-transformation into more innovation-driven enterprises

The push towards innovative drugs (globally, not just in China) will also present excellent opportunities for the best of China’s contract research organisations (CROs) or contract development and manufacturing organisations (CDMOs), including the likes of WuXi Biologics and Tigermed. There are also opportunities in the medical device sector and some medical consumables, as these markets continue to see strong demand.

Conclusion

As important as reducing the cost of generic drug prices, improving drug quality and development of high efficacy innovative drugs are also the primary focus of China’s healthcare reform.

Dramatic regulatory changes in the Chinese pharmaceutical sector, which triggered an indiscriminate sell-off when the policy was initially announced in 2018, have significantly disrupted the existing valuation system and the outlook on China’s pharma stocks. Such a radical regulatory overhaul is comprehensively redefining the Chinese pharma industry. Established business models, R&D plans and marketing mechanisms now no longer work as effectively in the new market environment. While some industry leaders have struggled to adapt, others have already started self-transformation into more innovation-driven enterprises, or sought to become vertically integrated to establish cost advantages. At this critical juncture in the industry, we believe it is the companies that can evolve the fastest which will survive and thrive, ultimately tapping into a multi-billion drug market with large numbers of therapeutic areas that remain underpenetrated.


Regulatory information and risk warnings

This information is issued and approved by Martin Currie Investment Management Limited (‘MCIM’). It does not constitute investment advice.
Market and currency movements may cause the capital value of shares, and the income from them, to fall as well as rise and you may get back less than you invested.
The opinions contained in this document are those of the named manager(s). They may not necessarily represent the views of other Martin Currie managers, strategies or funds.
The information provided should not be considered a recommendation to purchase or sell any particular security. It should not be assumed that any of the security transactions discussed here were or will prove to be profitable.